Amino Acid Supplementation in Continuous Renal Replacement Therapy (AARRT)

Karolinska University Hospital

Status: Enrolling

Conditions: Acute Kidney Injury

Treatments: Dietary Supplement: Amino acid supplementation (Glavamin, Fresenius Kabi)

Study type: Interventional

Funder types: Other

Identifiers

NCT06835816

2023-07570-01

Details and patient eligibility

About

ICU patients treated with continuous renal replacement therapy is recruited prior to start of treatment.

Blood samples are drawn and then dialysis start without amino acid supplementation. After a few hours samples are drawn from blood and dialysate. Then patients are given amino acid supplementation (33.5g/24hrs) for 20-24 hours. New samples are drawn and amino acid supplementation is increased to 67g/24hrs and new samples are drawn after additional 24 hours. Then CRRT will continue with the full amino acid supplementation (standars of care).

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Dialysis where amino acid supplementation is planned by treating physician

Exclusion criteria

• Liver failure
• Muscle disease
• Neurodegenerative disease

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

All patients

Experimental group

Description:

All patients will start CRRT treatment without amino acid supplementation After a few hours samples are drawn from blood and dialysate Patients then receive low dose of supplementation for 24 hours (33.5g, 250 ml Glavamin, Fresenius Kabi) and new samples are drawn After that patients receive full supplementation (67g, 500 ml Glavamin, Fresenius Kabi) for the rest the of CRRT treatment. After 24 hours of this treatment new samples are drawn.

Treatment:

Dietary Supplement: Amino acid supplementation (Glavamin, Fresenius Kabi)